MARKET

LJPC

LJPC

La Jolla Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.880
-0.050
-1.27%
After Hours: 3.900 +0.02 +0.52% 19:22 05/07 EDT
OPEN
4.010
PREV CLOSE
3.930
HIGH
4.150
LOW
3.830
VOLUME
273.83K
TURNOVER
--
52 WEEK HIGH
8.10
52 WEEK LOW
3.357
MARKET CAP
106.48M
P/E (TTM)
-2.6894
1D
5D
1M
3M
1Y
5Y
La Jolla Pharmaceutical (LJPC) Misses Q1 Earnings Estimates
Zacks.com · 1d ago
La Jolla Pharmaceutical shares rise on Q1 topline beat
La Jolla Pharmaceutical (LJPC) shares rise more than 10% during premarket trading after the company posted first-quarter revenue that beat Wall Street estimates.The company's total revenue increased 349.8% to $34.1M, beating analysts' estimate
Seekingalpha · 1d ago
La Jolla Pharmaceutical EPS misses by $0.14, beats on revenue
La Jolla Pharmaceutical (LJPC): Q1 GAAP EPS of $0.42 misses by $0.14.Revenue of $34.14M (+349.8% Y/Y) beats by $0.99M.As of March 31, 2021 and December 31, 2020, La Jolla had
Seekingalpha · 1d ago
BRIEF-La Jolla Pharmaceutical Co Announces Financial Results For Q1
reuters.com · 1d ago
La Jolla Pharmaceutical Q1 EPS $0.42 Up From $(0.32) YoY, Sales $34.14M Up From $7.59M YoY
La Jolla Pharmaceutical (NASDAQ:LJPC) reported quarterly earnings of $0.42 per share. This is a 231.25 percent increase over losses of $(0.32) per share from the same period last year. The company reported $34.14
Benzinga · 1d ago
La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2021 and Highlights Corporate Progress
La Jolla Pharmaceutical Company (Nasdaq: LJPC), which is dedicated to the development and commercialization of innovative therapies that improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three ...
BusinessWire · 1d ago
10-Q: LA JOLLA PHARMACEUTICAL CO
(EDGAR Online via COMTEX) -- Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 1d ago
-- Earnings Flash (LJPC) LA JOLLA PHARMACEUTICAL COMPANY Reports Q1 Revenue $34.1M
MT Newswires · 2d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LJPC. Analyze the recent business situations of La Jolla Pharm through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LJPC stock price target is 9.33 with a high estimate of 15.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 134
Institutional Holdings: 31.23M
% Owned: 113.81%
Shares Outstanding: 27.44M
TypeInstitutionsShares
Increased
19
717.95K
New
7
128.48K
Decreased
21
697.66K
Sold Out
6
173.87K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.53%
Pharmaceuticals & Medical Research
+1.04%
Key Executives
Chairman/Director
Kevin Tang
Chairman/Director
kevin Tang
President/Chief Executive Officer/Director
Larry Edwards
Chief Financial Officer/Chief Accounting Officer
Michael Hearne
Independent Director
Laura Douglass
Independent Director
Craig Johnson
Independent Director
David Ramsay
Independent Director
Robert Rosen
No Data
  • All
  • Financials
  • Insiders
More
About LJPC
La Jolla Pharmaceutical Company is focused on development and commercialization of therapies for patients suffering from life-threatening diseases. The Company’s products include GIAPREZA, XERAVA, LJPC-0118 and LJPC-401. The GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. The XERAVA (eravacycline) is a tetracycline class antibacterial indicated for the treatment of intra-abdominal infections in patients 18 years of age and older. The LJPC-0118 (I.V. artesunate) is the Company’s investigational product for the treatment of malaria. The LJPC-401 (synthetic human hepcidin) is the Company’s investigational product for the treatment of conditions characterized by iron overload.

Webull offers kinds of La Jolla Pharmaceutical Company stock information, including NASDAQ:LJPC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LJPC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LJPC stock methods without spending real money on the virtual paper trading platform.